Clinical Trial Update: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a new chemotherapy agent for non-small cell lung cancer reports safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Unnamed chemotherapy agent

Snippet

Sponsor: Bayer | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED